Anna C. Sick-Samuels

Anna C. Sick-Samuels

Auto-generated profile, based on publicly available information

Anna C. Sick-Samuels

Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2023 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
VFValeria Fabre
Valeria Fabre
ADAngelina Davis
Angelina Davis
DDDaniel J. Diekema
Daniel J. Diekema
BGBruno Granwehr
Bruno Granwehr
MHMary K. Hayden
Mary K. Hayden
DMDaniel J. Morgan
Daniel J. Morgan
Executive summary: We provide an overview of diagnostic stewardship with key concepts that include the diagnostic pathway and the multiple points where interventions can be implemented, strategies for interventions, the importance of multidisciplinary collaboration, and key microbiologic diagnostic tests that should be considered for diagnostic stewardship. The document focuses on microbiologic laboratory testing for adult and pediatric patients and is intended for a target audience of healthcare workers involved in diagnostic stewardship interventions and all workers affected by any step of the diagnostic pathway (ie, ordering, collecting, processing, reporting, and interpreting results of a diagnostic test). This document was developed by the Society for Healthcare Epidemiology of America Diagnostic Stewardship Taskforce.

1 August 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ZWZhihao Wu
Zhihao Wu
TLThomas W. Lauer
Thomas W. Lauer
ASAnna Sick
Anna Sick
SHSean F. Hackett
Sean F. Hackett
PCPeter A. Campochiaro
Peter A. Campochiaro
Age-related macular degeneration (AMD), the leading cause of severe vision loss in the elderly, is a complex disease that results from genetic modifications that increase susceptibility to environmental exposures. Smoking, a major source of oxidative stress, increases the incidence and severity of AMD, and antioxidants slow progression, suggesting that oxidative stress plays a major role. Polymorphisms in the complement factor H (CFH) gene that reduce activity of CFH increase the risk of AMD. In this study we demonstrate an interaction between these two risk factors, because oxidative stress reduces the ability of an inflammatory cytokine, interferon-γ, to increase CFH expression in retinal pigmented epithelial cells. The interferon-γ-induced increase in CFH is mediated by transcriptional activation by STAT1, and its suppression by oxidative stress is mediated by acetylation of FOXO3, which enhances FOXO3 binding to the CFH promoter, reduces its binding to STAT1, inhibits STAT1 interaction with the CFH promoter, and reduces expression of CFH. Expression of SIRT1, a mammalian homolog of NAD-dependent protein deacetylase sir2, attenuated FOXO3 recruitment to the CFH regulatory region and reversed the H2O2-induced repression of CFH gene expression. These data suggest an important interaction between environmental exposure and genetic susceptibility in the pathogenesis of AMD and, by elucidating molecular signaling involved in the interaction, provide potential targets for therapeutic intervention.

1 March 2021 in BMJ
Verified
Journal Article
Closed access
PDF file
JRJessica H Rubens
Jessica H Rubens
NANadine Peart Akindele
Nadine Peart Akindele
MTMegan M Tschudy
Megan M Tschudy
ASAnna C Sick-Samuels
Anna C Sick-Samuels

1 June 2013 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
ASAnna C. Sick
Anna C. Sick
Christoph Ulrich LehmannChristoph Ulrich Lehmann
Christoph Ulrich Lehmann
PTPranita D. Tamma
Pranita D. Tamma
CLCarlton K. K. Lee
Carlton K. K. Lee
AAAllison L. Agwu
Allison L. Agwu
Objective.: To evaluate an internet-based preapproval antimicrobial stewardship program for sustained reduction in antimicrobial prescribing and resulting cost savings.Design.: Retrospective cohort study and cost analysis.Methods.: Review of all doses and charges of antimicrobials dispensed to patients over 6 years (July 1, 2005–June 30, 2011) at a tertiary care pediatric hospital.Results.: Restricted antimicrobials account for 26% of total doses but 81% of total antimicrobial charges. Winter months (November–February) and the oncology and infant and toddler units were associated with the highest antimicrobial charges. Five restricted drugs accounted for the majority (54%) of charges but only 6% of doses. With an average approval rate of 91.5% (95% confidence interval [CI], 91.1%–91.9%), the preapproval antibiotic stewardship program saved $103,787 (95% CI, $98,583–$109,172) per year, or $14,156 (95% CI, $13,446–$14,890) per 1,000 patient-days.Conclusions.: A preapproval antimicrobial stewardship program effectively reduces the number of doses and subsequent charges due to restricted antimicrobials years after implementation. Hospitals with reduced resources for implementing postprescription review may benefit from a preapproval antimicrobial stewardship program. Targeting specific units, drugs, and seasons may optimize preapproval programs for additional cost savings.

1 April 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
PTPranita D. Tamma
Pranita D. Tamma
YFYunfan Fan
Yunfan Fan
YBYehudit Bergman
Yehudit Bergman
ASAnna C. Sick-Samuels
Anna C. Sick-Samuels
AHAlice J. Hsu
Alice J. Hsu
DGDavid E. Greenberg
David E. Greenberg
We report our clinical experience treating a 2-month-old infant with congenital diaphragmatic hernia who experienced prolonged bacteremia with Burkholderia cepacia complex (Bcc) despite conventional antibiotic therapy and appropriate source control measures. The infection resolved after initiation of ceftazidime-avibactam. Whole-genome sequencing revealed that the isolate most closely resembled B. contaminans and identified the mechanism of resistance that likely contributed to clinical cure with this agent. Ceftazidime-avibactam should be considered salvage therapy for Bcc infections if other treatment options have been exhausted.

7 April 2021 in Pediatrics
Verified
Journal Article
Open access
PDF file
ASAnna C. Sick-Samuels
Anna C. Sick-Samuels
MLMatthew Linz
Matthew Linz
JBJules Bergmann
Jules Bergmann
JFJames C. Fackler
James C. Fackler
SBSean M. Berenholtz
Sean M. Berenholtz
AMAaron M. Milstone
Aaron M. Milstone
Clinicians commonly obtain endotracheal aspirate cultures (EACs) in the evaluation of suspected ventilator-associated infections. However, bacterial growth in EACs does not distinguish bacterial colonization from infection and may lead to overtreatment with antibiotics. We describe the development and impact of a clinical decision support algorithm to standardize the use of EACs from ventilated PICU patients. We monitored EAC use using a statistical process control chart. We compared the rate of EACs using Poisson regression and a quasi-experimental interrupted time series model and assessed clinical outcomes 1 year before and after introduction of the algorithm. In the preintervention year, there were 557 EACs over 5092 ventilator days; after introduction of the algorithm, there were 234 EACs over 3654 ventilator days (an incident rate of 10.9 vs 6.5 per 100 ventilator days). There was a 41% decrease in the monthly rate of EACs (incidence rate ratio [IRR]: 0.59; 95% confidence interval [CI] 0.51–0.67; P < .001). The interrupted time series model revealed a preexisting 2% decline in the monthly culture rate (IRR: 0.98; 95% CI 0.97–1.0; P = .01), immediate 44% drop (IRR: 0.56; 95% CI 0.45–0.70; P = .02), and stable rate in the postintervention year (IRR: 1.03; 95% CI 0.99–1.07; P = .09). In-hospital mortality, hospital length of stay, 7-day readmissions, and All Patients Refined Diagnosis Related Group severity and mortality scores were stable. The estimated direct cost savings was $26 000 per year. A clinical decision support algorithm standardizing EAC obtainment from ventilated PICU patients was associated with a sustained decline in the rate of EACs, without changes in mortality, readmissions, or length of stay.